浩欧博（688656）8月1日主力资金净流入2236.55万元

Group 1 - The core viewpoint of the news is that Jiangsu Haooubo Biopharmaceutical Co., Ltd. has experienced a decline in both revenue and net profit in its latest quarterly report, indicating potential challenges for the company [1][3]. - As of August 1, 2025, the company's stock closed at 121.4 yuan, down 3.13%, with a trading volume of 19,000 hands and a transaction amount of 237 million yuan [1]. - The latest quarterly report shows total operating revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit attributable to shareholders of 1.64 million yuan, down 56.97% year-on-year [1]. Group 2 - The company has a current ratio of 1.558, a quick ratio of 0.878, and a debt-to-asset ratio of 18.80%, indicating its liquidity and financial stability [1]. - Jiangsu Haooubo has made investments in 6 companies and participated in 181 bidding projects, showcasing its active engagement in the market [2]. - The company holds 41 trademark registrations and 112 patents, along with 505 administrative licenses, reflecting its focus on intellectual property and regulatory compliance [2].